Every Form 4 that KORU Medical Systems, Inc. (KRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KRMD filings page.
KORU Medical Systems, Inc. (KRMD) reported that its Chief Commercial Officer, Adam R. Kalbermatten, purchased 32,000 shares of common stock on September 8, 2026, in an open-market or private transaction at $3.16 per share, bringing his directly held stake to 394,017 shares. The filing indicates this trade was not made pursuant to a Rule 10b5-1 trading plan, and it includes a standard disclaimer that the reporting person is not admitting beneficial ownership beyond what is required.
KORU Medical Systems, Inc. reported that Chief Commercial Officer Adam R. Kalbermatten had 75,000 shares of common stock delivered on July 28, 2026 upon vesting of previously granted restricted stock units, each converting into one share. On the same date, 25,483 shares were withheld at $4.26 per share to satisfy tax obligations related to the vesting. The transactions were reported as direct holdings and not under a Rule 10b5-1 trading plan.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems, Inc. reported that President and CEO Adam R. Kalbermatten received a grant of 284,091 Performance Stock Units tied to long-term performance goals. According to the award terms, 213,068 units may vest based on a target for the company’s net sales growth on or prior to 12/31/2030, and 71,023 units may vest based on achieving a specified market capitalization target as of 12/31/2030. The award represents a performance-based equity incentive linked to both operating and market outcomes.
KALBERMATTEN ADAM R reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems reported that President and CEO Adam R. Kalbermatten received a grant of 286,697 Performance Stock Units, each tied to an equal number of common shares. These awards were made under his amended and restated employment agreement as part of equity-based compensation.
According to the performance terms, 215,023 units may vest based on achieving a target level of the company's net sales growth on or prior to 12/31/2030, and 71,674 units may vest based on reaching a specified company market capitalization at 12/31/2030. All 286,697 units are reported as directly held following this grant.
KORU Medical Systems director Edward Wholihan received a grant of 3,571 shares of Common Stock, valued at $4.20 per share. This is a compensation-related award reported as an acquisition, not an open-market purchase. After the grant, his direct ownership totals 51,312 shares.
KORU Medical Systems director Matin Shahriar received a grant of common stock as part of equity compensation. On the reported date, Shahriar acquired 3,571 shares of KORU Medical Systems, Inc. common stock at $4.20 per share in a non-derivative award transaction.
Following this grant, Shahriar directly holds 101,144 shares of KORU Medical Systems common stock. This filing reflects a stock award rather than an open-market purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of 3,571 shares of Common Stock at $4.20 per share. This was a compensation-related award, not an open-market purchase. Following the grant, she directly holds a total of 98,514 KORU Medical Systems shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director R. John Fletcher received a grant of 5,357 shares of Common Stock at $4.20 per share. This was a compensation-related award rather than an open-market purchase. After the grant, he directly owns 232,157 shares, indicating the award is a relatively small addition to his existing position.
CASCELLA ROBERT reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Robert Cascella received a grant of 3,571 shares of Common Stock at $4.20 per share as a compensation-related award. After this Form 4 transaction, he directly owns 98,155 shares of KORU Medical Systems common stock.
KORU Medical Systems director and major holder reports stock grant. A Form 4 shows an entity associated with Horton Capital receiving a grant or other acquisition of 3,571 shares of KORU Medical common stock at $0.00 per share.
After this grant, Horton Capital Partners Fund, L.P. is reported with 5,069,541 shares held indirectly, while Joseph M. Manko Jr. also reports 782,547 shares held directly. The filing reflects a compensation or award-type acquisition rather than an open-market purchase or sale.
KORU Medical Systems, Inc. President and Chief Commercial Officer Adam R. Kalbermatten reported open-market purchases of company common stock. On one date, he bought 7,500 shares at $3.93 per share and 5,000 shares at $3.96 per share, for a total of 12,500 shares acquired directly.
KORU Medical Systems, Inc. Chief Technology Officer Eric Schiller purchased Common Stock in the open market. On May 18, 2026, he bought 5,000 shares at an average price of $3.9125 per share. Following this transaction, he directly owns 5,000 shares of KORU Medical Systems common stock.
KORU Medical Systems, Inc. CEO Linda M. Tharby bought additional company stock in the open market. On May 15, 2026, she purchased 1,191 shares of Common Stock at $3.92 per share. After this transaction, she directly owned 620,622 shares of KORU Medical common stock.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported an open-market purchase of 1,191 shares of the company’s Common Stock on May 15, 2026. After this transaction, she directly owns a total of 620,622 Common Stock shares.
KORU Medical Systems Chief Executive Officer Linda M. Tharby reported routine equity compensation activity. On May 14, she acquired 13,977 shares of common stock through the vesting of restricted stock units, while 7,326 shares were withheld at $3.94 per share to cover tax obligations.
KORU Medical Systems Chief Operating Officer Christopher Pazdan reported routine equity compensation activity. On the vesting of restricted stock units, he acquired 5,327 shares of common stock and 1,470 shares were withheld to satisfy tax obligations at a value of $3.94 per share. Following these transactions, he holds just over 310,000 shares directly.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan bought 5,000 shares of Common Stock in an open-market purchase at $3.88 per share. Following this transaction, he directly owns 305,131 shares.
KORU Medical Systems Chief Financial Officer Thomas Edward Adams reported routine equity compensation activity involving restricted stock units. On May 14, 2026, common stock was issued upon vesting of RSUs, each unit representing a contingent right to receive one share of common stock upon vesting.
In connection with this vesting, 2,900 shares of common stock were disposed of at $3.94 per share to satisfy tax obligations, while 8,193 shares were acquired through a derivative exercise/conversion. Following these transactions, Adams directly holds 313,440 shares of KORU Medical common stock. These are not open-market buy or sell transactions but compensation-related events.
KORU Medical Systems, Inc. Chief Financial Officer Thomas Edward Adams bought additional company stock in the open market. He purchased a total of 5,500 shares of common stock in two open-market transactions, paying $3.90 and $3.86 per share.
Manko Joseph M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems insider group reported an additional share award. On March 31, 2026, an entity identified as Horton Capital Partners Fund, L.P., which is associated with a ten percent owner, received a grant of 3,472 shares of Common Stock at $0.00 per share, reported as indirect ownership.
The filing also shows that, after this award, the indirectly held position reported for this fund stands at 5,065,970 shares of KORU Medical Systems Common Stock, while a separate direct holding line reflects 782,547 shares. This amendment mainly updates the recorded ownership levels rather than reflecting open‑market trading activity.
Matin Shahriar reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Matin Shahriar received a compensation-related grant of 3,472 shares of common stock at an indicated value of $4.32 per share. After this award, he directly holds 97,573 common shares. This was an equity grant, not an open-market stock purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of Common Stock reported in a Form 4. She was awarded 3,472 shares at a value of $4.32 per share as a compensation-related grant, not an open-market purchase. Following this award, she directly holds 94,943 shares of KORU Medical Systems common stock.
KORU Medical Systems director Edward Wholihan received an award of 3,472 shares of Common Stock of KORU Medical Systems, Inc. The shares were granted at a price of $4.32 per share and are reported as directly owned.
Following this grant, Wholihan now directly holds 47,741 shares of Common Stock. This was recorded as a grant, award, or other acquisition on a Form 4 insider transaction report, rather than an open-market purchase or sale.
KORU Medical Systems director Robert Cascella received a stock grant, increasing his direct holdings. He was awarded 3,472 shares of Common Stock as a grant or award at an indicated price of $4.32 per share. Following this compensation-related acquisition, he directly owns 94,584 shares. This is a routine equity award rather than an open-market purchase or sale.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director R. John Fletcher received an equity grant of common stock. On the reported date, he was awarded 5,208 shares of KORU Medical Systems, Inc. common stock at an indicated value of $4.32 per share, reflecting compensation rather than an open-market purchase. Following this grant, he directly holds a total of 226,800 common shares, aligning his interests further with other shareholders.
Manko Joseph M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems insiders reported a new share award. On March 31, 2026, Horton Capital Partners Fund, L.P., a 10% owner, received a grant of 3,472 shares of KORU Medical Systems common stock at no cost, increasing its indirectly held position to 5,065,970 shares.
The filing also shows a separate direct holding of 500,200 common shares reported by the insider group as of the same date, providing context for their overall ownership stake.
KORU Medical Systems reported that its President and Chief Commercial Officer, Adam R. Kalbermatten, received new equity awards as part of his compensation. He was granted 45,098 restricted stock units and 45,098 performance stock units, each representing the right to receive one share of common stock upon vesting.
The restricted stock units vest in equal annual installments beginning on March 17, 2027. The performance stock units vest based on achievement of performance conditions measured as of December 31, 2028, with potential payout ranging from 0% to 150% of the 45,098 target units, or fully upon a change in control before that date.
He also received options to buy 67,779 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. All transactions are grants or awards, not open-market purchases or sales.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan reported several equity compensation transactions. He received 5,064 shares of common stock from vested restricted stock units, with 1,628 shares withheld to cover tax obligations, leaving 3,436 shares held directly.
On the same grant date, he was awarded 31,226 restricted stock units that vest in equal increments on March 17, 2027 and each first, second, and third anniversary of that date, and 31,226 performance stock units that can pay out between 0% and 150% of target based on performance as of December 31, 2028, or fully upon a change in control before then. He also received an option to buy 46,929 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. All events are compensation-related and do not involve open-market buying or selling.
KORU Medical Systems reported several equity transactions for Chief Financial Officer Thomas Edward Adams. He received grants of 38,918 restricted stock units and 38,918 performance stock units, each representing the right to receive one share of common stock upon vesting. The restricted stock units were granted under the 2024 Omnibus Equity Incentive Plan and vest in equal increments on March 17, 2027 and on the first, second and third anniversaries of that date. The performance stock units are tied to performance through December 31, 2028, with potential payout between 0% and 150% of the 38,918-share target, and they vest in full at the reported amount upon a change in control before that date. Adams also received an option to buy 58,490 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. In a related event, 5,404 shares of common stock were issued upon vesting of restricted stock units, and 2,123 of those shares were withheld at $4.28 per share to satisfy tax obligations, leaving 3,281 shares held directly.
KORU Medical Systems reported that Chief Executive Officer Linda M. Tharby received common shares through equity compensation and had a portion withheld for taxes. On March 16, 2026, she acquired 15,968 shares of common stock at no cost upon vesting of restricted stock units. Of these, 5,756 shares were withheld at $4.28 per share to satisfy tax obligations related to the vesting. After these transactions, she directly holds 10,212 shares of KORU Medical Systems common stock. These events reflect routine compensation-related activity rather than open-market buying or selling.
KORU Medical Systems, Inc. insider entities associated with director and 10% owner Joseph M. Manko Jr. reported several transactions in common stock on February 13, 2026, all at a reported price of $0 per share under transaction code J.
After these transactions, Horton Capital Partners Fund, LP indirectly held 5,062,498 shares, Horton Capital Partners, LLC indirectly held 750,000 shares, and Manko directly held 782,547 shares. The filing emphasizes that it should not be construed as an admission of beneficial ownership of the reported securities.
KORU Medical Systems reported that its Chief Technology Officer, Eric Schiller, received new equity awards on January 2, 2026. He was granted 76,426 shares of common stock at a price of $0, described as restricted stock issued as an employment inducement award that will vest 25% annually starting on January 2, 2027. He was also granted an option to buy 232,297 shares of common stock with an exercise price of $5.7 per share, with one-fourth of the option scheduled to vest on January 2, 2027 and on each of the first, second and third anniversaries of that date.
KORU Medical Systems, Inc. granted its Chief Financial Officer, Thomas Adams, an award of 75,000 restricted stock units (RSUs)
One-fourth of the RSUs will vest on January 2, 202775,000 derivative securities$0 per unit
KORU Medical Systems, Inc. (KRMD) reported an insider ownership update on a Form 4 filed by multiple reporting persons identified as a director and 10% owner. On 11/26/2025, a transaction coded "J(1)" involved the disposition of 41,000 shares of common stock at a stated price of $0. Following this transaction, the filer reports 5,830,335 shares of common stock beneficially owned indirectly through Horton Capital Partners Fund, LP, and an additional 517,200 shares of common stock beneficially owned directly. The filing includes customary disclaimers that it should not be construed as an admission of beneficial ownership or of any filing obligation.
KORU Medical Systems (KRMD) reported an insider equity transaction. On 10/16/2025, the President and CEO was issued 29,463 shares of common stock at $4.08 per share under her employment agreement as the stock portion of the 2024 annual bonus (30% stock, 70% cash).
Following the transaction, she beneficially owned 1,052,626 shares. This includes 200,000 restricted stock awards that vest based on a market capitalization schedule prior to 3/15/27, and 600,000 restricted stock awards that vest based on net sales growth targets for fiscal years ended 12/31/22 through 12/31/25.
Edward Wholihan, a director of KORU Medical Systems, Inc. (KRMD), reported a purchase of 3,916 shares of the company’s common stock on 10/02/2025 at a price of $3.83 per share. Following the transaction the reporting person beneficially owned 41,688 shares. The filing is a Form 4 statement of changes in beneficial ownership and was signed by Thomas Adams as attorney-in-fact.
KORU Medical Systems director Matin Shahriar reported a purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. Following this transaction the reporting person beneficially owns 91,520 shares. The filing was submitted on Form 4 and signed by an attorney-in-fact.
Fletcher R. John, identified as Chairman of the Board of KORU Medical Systems, Inc. (KRMD), reported a purchase of 5,874 shares of the issuer's common stock at a price of $3.83 per share on 10/02/2025. After the transaction he beneficially owns 217,720 shares. The Form 4 notes the filing is submitted under a previously granted power of attorney and clarifies it should not be taken as an admission of beneficial ownership under Section 16. No derivative transactions or other security classes are reported.
KORU Medical Systems director Robert Cascella reported an open-market purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. After the transaction he beneficially owned 88,531 shares. The Form 4 was signed by an attorney-in-fact and includes a standard remark that a power of attorney has been previously filed.
Joseph M. Manko Jr., a director and reported 10% owner, filed a Form 4 for KORU Medical Systems, Inc. (KRMD). The filing shows a transaction dated 09/30/2025 where he acquired 3,916 shares of Common Stock at a reported price of $0, and reports 5,871,335 shares beneficially owned indirectly through Horton Capital Partners Fund, LP. The Form also reports a disposition of 517,200 shares.
The Form 4 is signed by Mr. Manko with signature dates of 10/02/2025. The filing references an Exhibit 99.1 for explanations of two notes tied to the reported acquisition and indirect ownership. No additional financial metrics, option holdings, or exercise/expiry dates are disclosed in the filing text provided.